

## **Company Presentation**

November 2014

#### Disclaimer

This document is confidential and is being made available to a limited number of persons for informational purposes only and for their exclusive use subject to the provisions below. This document is not intended to form the basis of any investment decision and should not be considered as a recommendation by Al Noor Hospitals Group Plc (the "Company"), or any other person in relation to the Company.

None of the information contained in this document has been verified by the Company. The Company makes no representations or warranties, express or implied, as to the adequacy, completeness or accuracy of any statement or other information contained herein or in any other oral or written information furnished or made available, nor as to the reasonableness of any assumption contained herein or therein and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. Nothing contained herein or therein is, or shall be relied upon as, a promise or representation, whether as to the past or the future. No party shall have any right of action against the Company or any other person (including, for the avoidance of doubt, their respective employees, directors, officers, contractors, advisors, members, affiliates, successors and agents) in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to it in connection with the Company or its business.

This document contains forward-looking statements, opinions and/or projections prepared by the Company's management which involve significant elements of subjective judgement and analysis which may or may not be correct. Such forward-looking statements, opinions and projections are not guarantees of future performance and involve known and unknown risks and uncertainties. Other important factors could cause actual results to differ from the statements, opinions and projections contained herein. Forward-looking statements, opinions and projections are based on historical and/or current information that relate to future operations, strategies, financial results or other developments.

The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with the Company or in connection with any further investigation. Any recipient hereof should conduct its own independent analysis of the Company and the data contained or referred to herein or therein. In furnishing this document the Company does not undertake any obligation to provide the recipient with access to any additional information or to update this document or additional information or to correct any inaccuracies therein which may become apparent.

This document must not be copied, reproduced, distributed or passed to others at any time.

This document does not constitute investment advice and the Company undertakes no obligation with respect to the recipient hereof.



## Al Noor at a glance

<sup>1</sup> Al Bateen and Al Baniyas Clinic was opened in early 2014.


<sup>2</sup> GICC acquisition announced in December 2013 and completed in Q1 2014.

#### Geographic presence in Abu Dhabi, Dubai and Oman Hospitals New Centres added in 2013 and H1 2014 **Openings Key Statistics (2013)** Iran • 80 operational beds Khalifa Hospital Sanava Clinic • 168 physicians Persian Gulf 223 nurses Qatar Dubai Mamura Clinic • 14,783 in-patients Abu Dhabi • 537,825 out-patients Gulf of Oman Oman Clinic • 50 operational beds Madinat Zaved Ain Hospital • 101 physicians Muscat Al Bateen Clinic<sup>1</sup> Saudi Arabia • 152 nurses Oman • 8,395 in-patients Al Baniyas Clinic<sup>1</sup> • 349,077 out-patients Emirate of Abu Dhabi Other Emirates of the UAE Al Noor Location Acquisitions • 94 operational beds Medical Centres (14) • 155 physicians • Beda Zaved (2) • Muscat, Oman (1) • Al Yahar (1) Al Madar Medical Centre • 257 nurses • Al Ain (2) Sanaya (1) • Jumeirah, Dubai (1) • 17,297 in-patients • Mussafah (2) • Mamura (1) • Al Bateen<sup>1</sup> (1) Manchester Clinic • 445,682 out-patients • Al Mirfa (1) • Al Rahba (1) Gulf International Cancer Source: Company information



Centre<sup>2</sup>

## **Key Investment Highlights**





## 1


## Attractive and highly investable home markets (1/2)

#### Several trends driving demand for healthcare

- Growing ageing population with increased life expectancy
- Increasing incidence of lifestyle conditions such as diabetes, obesity, cancer, respiratory and cardiovascular diseases
- Renewed focus on market gaps identified by HAAD
- Introduction of mandatory healthcare insurance in other emirates of the UAE







#### Demand for healthcare services expected to continue increasing across the UAE

Source: Euromonitor, WHO, OECD, International Diabetes Foundation, World Bank, Global Insight

- Obesity defined as a body mass index (BMI) of 30 kg/m<sup>2</sup> or more. Obese population measured as percent of population aged 15 or older (data as of 2011).
- <sup>2</sup> Diabetes comparative prevalence as percent of population as defined by WHO. Excludes countries with population of less than 500,000 (estimates for 2012).




## 1

## Attractive and highly investable home markets (2/2)

#### Healthcare expenditure to continue increasing in the UAE

- UAE healthcare reforms are driving higher per capita spending with hospitals expected to benefit from resulting market trends
- Despite high GDP per capita, healthcare expenditure in the UAE continues to lag developed countries
- Abu Dhabi expected to require up to 1,900 additional physicians and 1,700 additional beds in 2011-2021


#### Hospital beds per 1,000 people in selected countries (2011)




#### Physicians per 1,000 people in selected countries (2011)



#### Per capita healthcare expenditure by country (2011)



#### Increasing private healthcare sector expenditure (as a % of total)




Compared with more developed economies, significant gaps exist in the provision of healthcare in the UAE

Source: Euromonitor, WHO, World Bank, HAAD Statistics (2011), Espicom Medical Markets Fact Book (2012), RNCOS, The National newspaper (UAE)



# Significant scale and market leading position in the Abu Dhabi private hospital sector



#### ...with high barriers to entry

- Stringent medical facility and personnel licensing requirements
  - Decentralised system with each emirate adopting its own policies and regulatory body
- ✓ Ability to develop and maintain strong relationships with payors and suppliers
  - Function of both scale and longstanding relationships
- ✓ Need for sufficient economies of scale and efficient operating structures in order to achieve profitability

#### Al Noor is the clear market leader in Abu Dhabi

Source: Company information, HAAD Statistics (2012)

<sup>&</sup>lt;sup>1</sup> Market share calculation based on the number of private in-patient and out-patient encounters (excluding emergency procedures) in the Emirate of Abu Dhabi.

<sup>&</sup>lt;sup>2</sup> Information for Al Noor as of 31-Dec-2013 and information for competitors as of 2012 based on HAAD Statistics and publicly available company information.

## 3

# High quality care, differentiated positioning and operational excellence (1/3)

#### Evidence of excellence<sup>1</sup>

- First hospital to be designated by American Safety & Health Institute as a Basic and Advanced Training Centre
- First private hospital in the UAE to operate and manage a Governmental Medical Facility (Ruwais Hospital)
- First private hospital in Abu Dhabi City to obtain JCI accreditation
- Well-invested, JCI-accredited facilities with some of the most advanced medical technologies in the UAE
  - Airport Road hospital received 99.4% JCI score in Dec-2012 survey
- Al Noor facilities score highly in HAAD customer satisfaction surveys:
  - Airport Road and Khalifa hospitals ranked #1 and #3, respectively, in Abu Dhabi; Al Ain hospital ranked #1 in Al Ain
- 43% of Al Noor's consultant physicians are HAAD Tier 1<sup>3</sup>

















Focus on quality contributes to Al Noor's differentiated market positioning

<sup>&</sup>lt;sup>1</sup> Source: Company information

<sup>&</sup>lt;sup>2</sup> Source: HAAD Statistics (2011)

<sup>&</sup>lt;sup>3</sup> HAAD Tier 1 includes physicians with fellowships, boards or certification from Australia, New Zealand, Belgium, Canada, France, Germany, Austria, Switzerland, Ireland, South Africa, UK and USA.

# High quality care, differentiated positioning and operational excellence (2/3)



<sup>&</sup>lt;sup>1</sup> Source: HAAD Statistics (2011)

<sup>&</sup>lt;sup>2</sup> Source: Company information



## 3

# High quality care, differentiated positioning and operational excellence (3/3)

Percentile Scores Based on Indicator Values for Diabetes Performance for Selected Abu Dhabi Hospitals

	Diabetes KPIs									
	Well controlled diabetics	Latest HbA1c <7%	Moderate & well controlled Diabetics	Latest HbA1c <7.5%	Poorly controlled diabetics	Latest HbA1c >9%	HbA1c	Annua Lipid profile	al tests Renal	Eye exam
SKMC	79%	69%	83%	66%	21%	59%	79%	86%	66%	48%
Imperial College London Diabetes Centre	100%	59%	97%	59%	0%	0%	100%	100%	100%	3%
NMC Specialty	52%	72%	48%	69%	76%	79%	38%	72%	72%	0%
Al Noor – Airport Road	93%	93%	90%	86%	31%	62%	86%	93%	97%	79%
90-100 Percentile Scores 80-89 Percentile Scores										


Al Noor is among the leading providers of diabetes treatment in Abu Dhabi


Source: HAAD Statistics (2011), Encounters with start date of 01-Jan-2011 to 31-Dec-2011 Note: Hospitals ordered by diabetes patient volumes. Percentile scores for reference group based on top 30 hospitals




### 4

## Attractive financial profile









Source: Company information

<sup>&</sup>lt;sup>1</sup> Including out-patient ancillary services such as laboratory, radiology and pharmacy.

<sup>&</sup>lt;sup>2</sup> Underlying EBITDA excludes management fee (management fee paid in 2010 and 2011 only), first time LSE registration fees of USD 0.3m and acquisition-related administrative expenses of USD 0.5m in 2013.

## Multiple, executable growth prospects

Inorganic growth opportunities					
Existing Geographies	Maintain market share	<ul> <li>Continue to grow market share in the Emirate of Abu Dhabi through the strategic acquisition of established hospitals or medical centres</li> <li>Potential acquisition of a group of medical centres in 2013</li> </ul>			
	Service line expansion	<ul> <li>Service gaps identified in speciality areas</li> <li>Acquire new services through strategic equity investments in, or acquisitions of, specialised hospitals or centres</li> <li>Acquisition in 2014 of only private oncology centre in Emirate of Abu Dhabi</li> </ul>			
New	Rest of the UAE	<ul> <li>Introduction of mandatory insurance</li> <li>Acquisition of hospitals/medical centres in the rest of the UAE</li> <li>Well-positioned to capitalise on growth in neighbouring emirates</li> </ul>			
Geographies	Wider GCC region	<ul> <li>Expected introduction of mandatory insurance</li> <li>Long-term acquisition opportunities in the wider GCC by 2016/2017</li> <li>Expansion through partnerships with existing providers</li> </ul>			

Source: Company information

## H1 2014 Update

## Key takeaways from H1 2014 results

#### 1 Financial Highlights

- Strong top line growth driven by improved operating performance and increased patient volumes
  - Net revenue grew by 25.2%
     in H1 2014 vs. H1 2013
- Growth in profit with margins remaining steady due to controlled operating costs despite the rise in medical staff expenses
  - 30.7%, 25.2% and 22.5% y-o-y growth in gross profit, Underlying EBITDA<sup>1</sup> and Underlying operating income<sup>1</sup>, respectively
- Cash generation is lower due to higher capital expenditure, and acquisitions concluded in H1 2014.

#### 2 Operating Results

- Strong growth in Outpatient volumes
  - Number of outpatient encounters +20% y-o-y
  - Number of inpatient admissions +1% y-o-y, lower than expected due to loss of Inpatient volume at Khalifa Street, offset by growth at the other hospitals.
- Acceleration in recruitment of physicians and acquisitions was a key driver of patient volumes
  - Number of FTE revenuegenerating doctors higher by 106 (+26.8%) in H1 2014 vs. H1 2013

#### 3 Delivering on Strategy

- Operational initiatives deployed to drive growth and efficiencies
  - Expansion of clinical services and centralisation of selected functions
  - Improved utilisation with continued focus on quality
- Positive developments in medical centre roll-out and M&A strategy
  - Opened three medical centres in H1 2014.
  - A potential service line expansion in Abu Dhabi
  - One potential acquisition opportunity is being explored.

<sup>&</sup>lt;sup>1</sup> Adjusted for IPO-related costs and pre-IPO restructuring costs.



## Key takeaways from H1 2014 results

#### 1 Financial Highlights

- Strong top line growth driven by improved operating performance and increased patient volumes
  - Net revenue grew by 25.2%
     in H1 2014 vs. H1 2013
- Growth in profit with margins remaining steady due to controlled operating costs despite the rise in medical staff expenses
  - 30.7%, 25.2% and 22.5%
     y-o-y growth in gross profit,
     Underlying EBITDA¹ and
     Underlying operating
     income¹, respectively
- Cash generation is lower due to higher capital expenditure, and acquisitions concluded in H1 2014.

#### 2 Operating Results

- Strong growth in outpatient volumes
  - Number of outpatient encounters +20% y-o-y
  - Number of inpatient admissions +1% y-o-y, lower than expected due to loss of Inpatient volume at Khalifa Street, offset by growth at the other hospitals.
- Acceleration in recruitment of physicians and acquisitions was a key driver of patient volumes
  - Number of FTE revenuegenerating doctors higher by 106 (+26.8%) in H1 2014 vs. H1 2013

#### 3 Delivering on Strategy

- Operational initiatives deployed to drive growth and efficiencies
  - Expansion of clinical services and centralisation of selected functions
  - Improved utilisation with continued focus on quality
- Positive developments in medical centre roll-out and M&A strategy
  - Opened three medical centres in H1 2014.
  - A potential service line expansion in Abu Dhabi
  - One potential acquisition opportunity is being explored.

<sup>&</sup>lt;sup>1</sup> Adjusted for IPO-related costs and pre-IPO restructuring costs.



## Strong top line growth and margins

#### Profit & Loss Statement (in USDm)


H1 2013	H1 2014	Year-on-Year Growth
179.5	224.8	25.2%
75.3	98.4	30.7%
41.9%	43.8%	
37.7	46.2	22.5%
21.0%	20.6%	
34.1	45.6	33.7%
19.0%	20.3%	
41.3	51.7	25.2%
23.0%	23.0%	
	179.5  75.3  41.9%  37.7  21.0%  34.1  19.0%	179.5       224.8         75.3       98.4         41.9%       43.8%         37.7       46.2         21.0%       20.6%         34.1       45.6         19.0%       20.3%         41.3       51.7

<sup>&</sup>lt;sup>1</sup> Underlying metrics adjusted in 2013 - for IPO costs and pre-IPO restructuring costs.

#### Overview

- Net revenue grew by 25.2% in H1 2014 vs. prior year
- Drivers include:
  - Higher outpatient volumes (19.7% higher than in H1 2013)
  - Increase in the net number of revenue generating doctors by 31 in H1 2014.
  - Revenue from Acquired business equivalent to \$16.2m.
- Underlying Operating profit increased by 22.5% in H1 2014 vs. prior year
  - Reduced cost of medicine and consumables through better usage discipline partially offset by increase in medical staff costs.
- Underlying net profit increased by 33.7% in H1 2014 vs. prior year
  - Impact from lower interest costs following the repayment of loan, which was paid off in full in June 2013.
- Underlying EBITDA increased by 25.2% in H1 2014 vs. prior year
  - Stable Underlying EBITDA margin at ~23% for H1 2014 and H1 2013

## 1 Controlled operating costs



#### Overview

- Operating costs as percentage of net revenue have increased slightly
  - Medical staff costs mainly due to expanding the business, acquisitions and recruitment of a large number of doctors
  - SG&A -increased administrative costs in the three hospitals, PLC, corporate office and acquired assets.
  - The increase in the costs above was offset by lower consumables and rent as a percentage of revenue.
- Medical staff costs increased due to the doctor recruitment programme (including supporting medical staff)

Costs under control

## Improved working capital management

#### Receivable and payable days



#### Overview

- Trade Receivable days are steady despite higher business activity.
- Trade payable days have increased from Dec 2013 in line with the increase in business activity.
- Cash position is strong despite higher investment in Acquisition, New clinics and SAP investments.
  - \$86.3m as of 30-Jun-2014 (vs. \$107.5m as of 31-Dec-2013).

## Key takeaways from H1 2014 results

#### 1 Financial Highlights

- Strong top line growth driven by improved operating performance and increased patient volumes
  - Net revenue grew by 25.2% in H1 2014 vs. H1 2013
- Growth in profit with margins remaining steady due to controlled operating costs despite the rise in medical staff expenses
  - 30.7%, 25.2% and 22.5% young growth in gross profit, Underlying EBITDA<sup>1</sup> and Underlying operating income<sup>1</sup>, respectively
- Cash generation is lower due to higher capital expenditure, and acquisitions concluded in H1 2014.

#### 2 Operating Results

- Strong growth in outpatient volumes
  - Number of outpatient encounters +20% y-o-y
  - Number of inpatient admissions +1% y-o-y, lower than expected due to loss of Inpatient volume at Khalifa Street, offset by growth at the other hospitals.
- Acceleration in recruitment of physicians and acquisitions was a key driver of patient volumes
  - Number of FTE revenuegenerating doctors higher by 106 (+26.8%) in H1 2014 vs. H1 2013


#### 3 Delivering on Strategy


- Operational initiatives deployed to drive growth and efficiencies
  - Expansion of clinical services and centralisation of selected functions
  - Improved utilisation with continued focus on quality
- Positive developments in medical centre roll-out and M&A strategy
  - Opened three medical centres in H1 2014.
  - A potential service line expansion in Abu Dhabi
  - One potential acquisition opportunity is being explored.

<sup>&</sup>lt;sup>1</sup> Adjusted for IPO-related costs and pre-IPO restructuring costs.



## Strong growth in patient volumes






#### Overview

- Increase in patient volumes driven by:
  - Successful recruitment of physicians
  - Roll-out of medical centres
  - Acquisitions
  - Expansion of service offering
  - Continued focus on quality and recognition by patients and regulators
- Inpatient volume has not increased in line with expectations due to lower inpatient volume at Khalifa Street Hospital, which is undergoing refurbishment. This decrease is offset by growth in the other two hospitals.
- Conversion Ratio for H1 2014 was 2.1% (vs. 2.4% in H1 2013)

## Positive trend in recruitment of physicians

#### Number of FTE revenue-generating doctors



- Increase in number of revenue-generating doctors by:
  - 31 (+6.6%) since December 2013
  - 106 (+26.8%) since June 2013
  - Q2 hiring slowed down, resulting in no growth in doctor numbers in Q2. Attrition remained unchanged
  - On track to hit our recruitment targets for 2014: 40-50 more FTE revenue-generating doctors targeted by FY 2014 year-end.

Positive trend in recruitment of physicians, which is a core growth driver

Overview

<sup>\*</sup> Based on average no. of FTE Doctors for the period.

## Key takeaways from H1 2014 results

#### 1 Financial Highlights

- Strong top line growth driven by improved operating performance and increased patient volumes
  - Net revenue grew by 25.2%
     in H1 2014 vs. H1 2013
- Growth in profit with margins remaining steady due to controlled operating costs despite the rise in medical staff expenses
  - 30.7%, 25.2% and 22.5%
     y-o-y growth in gross profit,
     Underlying EBITDA¹ and
     Underlying operating
     income¹, respectively
- Cash generation is lower due to higher capital expenditure, and acquisitions concluded in H1 2014.

#### 2 Operating Results

- Strong growth in outpatient volumes
  - Number of outpatient encounters +20% y-o-y
  - Number of inpatient admissions +1% y-o-y, lower than expected due to loss of Inpatient volume at Khalifa Street, offset by growth at the other hospitals.
- Acceleration in recruitment of physicians and acquisitions was a key driver of patient volumes
  - Number of FTE revenuegenerating doctors higher by 106 (+26.8%) in H1 2014 vs. H1 2013

#### 3 Delivering on Strategy

- Operational initiatives deployed to drive growth and efficiencies
  - Expansion of clinical services and centralisation of selected functions
  - Improved utilisation with continued focus on quality
- Positive developments in medical centre roll-out and M&A strategy
  - Opened three medical centres in H1 2014.
  - A potential service line expansion in Abu Dhabi
  - One potential acquisition opportunity is being explored.

<sup>&</sup>lt;sup>1</sup> Adjusted for IPO-related costs and pre-IPO restructuring costs.

## Operational initiatives driving growth and efficiencies

#### Hospital-related initiatives

- Al Ain
  - New Hospital construction progressing well
  - Additional premises in adjacent building has been acquired to add more Clinics
- Khalifa Street
  - Refurbishment and Expansion of facilities on going

#### Other initiatives

- SAP implementation process commenced, Finance and Material Management modules completed.
- To enhance the reporting on Quality KPIs – software developments in progress
- Integration of acquisitions to derive synergy benefits

#### Results

- Increase in the number of outpatient encounters
- Better utilisation of available space with potential for further improvement
- Additional space being taken up to accommodate more clinics in 2015
- Expansion of medical services to cater for Industrial workers (ENEC and ICAD), occupational health clinics.
- Control of operating costs, despite increase in doctor numbers
- Improved internal processes and controls, with SAP

Al Noor continues to drive growth and efficiency through various operational initiatives

## Continued success in pursuing value-enhancing opportunities

- New primary care clinics
  - Four clinic openings in H1 2014, with strategic consolidation in Abu Dhabi and key wins servicing construction personnel
- Strong new build activity in Al Ain and Sharjah
- Potential acquisitions opportunities are being explored
  - Aimed at strengthening presence in Dubai, continuing consolidation strategy in Abu Dhabi and expanding service offering

Recently opened/contracted medical centres					
Bateen Clinic	Provides general medical services mainly to Thiqa patients	Abu Dhabi – Abu Dhabi	Q1 2014		
Baniyas Clinic	Provides general medical services mainly to Thiqa patients	Abu Dhabi – Abu Dhabi	Q1 2014		
ICAD Clinic	Provides general medical services mainly to labourers	Abu Dhabi – Abu Dhabi	Q2 2014		
ENEC	Provides medical services at Nuclear Plant under construction	Abu Dhabi – Abu Dhabi	Q3 2014		

Upcoming new build projects					
Hospital	• Construction underway for a new 40 bed hospital in Al Ain, expected to cater primarily to Thiqa patient base	Al Ain – Abu Dhabi	2016		
Medical Centres	<ul><li>Clinic in Sharjah</li><li>Clinic in Al Ain</li></ul>	<ul><li>Sharjah</li><li>Al Ain – Abu Dhabi</li></ul>	2015		

Multi-faceted growth strategy to drive expansion into new geographies and service offerings

## Q3 2014 Updates

#### Key Financial & Operational Highlights for 3 months to 30 September 2014

	Q3 2014	Q3 2013	Growth
	(US\$m)	(US\$m)	
Revenue	101.2	84.0	20.5%

- Al Noor continue to perform in line with management's expectation in Q3 2014, demonstrating strong revenue growth and stable EBITDA margins.
- Outpatient volumes increased significantly with growth at existing and new clinics. Inpatient volumes continued to be flat overall.
- Revenue generating physicians increased from 501 by the end of H1 2014 to 519 by end of Q3 2014, an increase of 18 physicians.

#### **Ongoing Initiatives**

- As part of the growth plans Al Noor continue to take up additional space for Khalifa Street Hospital in its
  existing building and also enhancing the interiors of the clinics and inpatient rooms to improve the patient
  experience.
- Construction on the new hospital in Al Ain continues as planned and is expected to commission the hospital in 2016.
- The fitting out of the medical centre in Sharjah continues as planned and is expected it to be operational in Q2 2015.



## Q3 2014 Updates

#### **Management Changes**

- Dr. Kassem Alom stepped down as Chief Executive, and remains on the board as Non-Executive Deputy Chairman.
- Mr. Ronald Lavater joined as Chief Executive of Al Noor. Mr. Lavater joins from Johns Hopkins Medicine International (JHI), a well-respected global healthcare company, where he served as a Senior Executive for the Middle East Region and from 2009 through 2013, as the Chief Executive Officer of the JCI accredited Corniche Hospital in Abu Dhabi, the largest maternity and neo-natal hospital in the UAE.
- Dr. Georges Feghali appointed Chief Medical Officer. Prior to joining Al Noor, Dr. Feghali was the Senior VP of Quality, Chief Medical Officer of TriHealth, a Cincinnati-based health system that includes tertiary teaching hospitals. Dr. Feghali is certified by the American Board of Internal Medicine and is a Certified Physician Executive.
- The Company announced the resignation of Dr. Jeffrey Staples from the position of Chief Operations Officer effective December 2014. A search to fill the position has already been initiated.

**Appendix: Additional Information** 

## Profit & loss statement (H1 2014 vs. H1 2013)

#### Profit & Loss Statement (in USDm)

			Year-on-Year
in USDm	H1 2013	H1 2014	Growth
Net revenue	179.5	224.8	25.2%
Cost of sales	(104.3)	(126.3)	
Gross profit	75.3	98.4	30.7%
Gross profit margin	41.9%	43.8%	
Operating expenses <sup>1</sup>	(37.6)	(52.2)	
Other income	0.0	0.0	
Underlying operating profit <sup>1</sup>	37.7	46.2	22.5%
Underlying Operating profit margin	21.0%	20.6%	
Finance income	0.9	0.3	
Finance cost	(4.4)	(0.9)	
Underlying net profit <sup>1</sup>	34.1	45.6	33.7%
Underlying Net profit margin	19.0%	20.3%	
Depreciation	3.6	5.5	
Net finance cost	3.6	0.6	
Underlying EBITDA <sup>1</sup>	41.3	51.7	25.2%
Underlying EBITDA margin	23.0%	23.0%	
Listing transaction cost	(6.1)		
Non-underlying finance cost	(2.9)		
Other non-underlying costs	(0.3)		

#### Overview

- Net revenue grew by 25.2% in H1 2014 vs. prior year
- Drivers include:
  - Higher outpatient and inpatient volumes (19.7% and 1.2% higher than in H1 2013, respectively)
  - Increase in the number of revenue generating doctors by 31 in H1 2014.
- Underlying Operating profit increased by 22.5% in H1 2014 vs. prior year
  - Increase in medical staff costs offset by lower consumables, and flat pharmacy costs
- Underlying net profit increased by 33.7% in H1 2014 vs. prior year
  - Impact from lower interest costs following the repayment of loan (the loan was paid off in full in June 2013)
- Underlying EBITDA increased by 25.2% in H1 2014 vs. prior year
  - Stable Underlying EBITDA margin at ~23% for H1 2014 and H1 2013

<sup>&</sup>lt;sup>1</sup> Underlying metrics of 2013 adjusted for IPO costs and pre-IPO restructuring costs.

## Balance sheet (H1 2014 vs. FY 2013)

Historical Balance Sheet (in USDm)					
	31-Dec-2013	30-Jun-2014			
Non-current assets					
Property and equipment	29.2	50.0			
Intangible assets and goodwill	20.1	30.2			
Prepayments and def Tax	0.1	2.7			
Total non-current assets	49.3	82.9			
Current assets					
Inventories	16.5	20.5			
Trade and other receivables	85.9	106.5			
Amounts due from related parties	1.2	1.5			
Short-term deposits	0.0	13.6			
Cash and cash equivalents	107.7	72.7			
Total current assets	211.3	214.7			
Total assets	260.6	297.6			
Non-current liabilities					
Trade and other payable	2.2	1.3			
Bank loans					
Employee benefits	11.5	13.4			
Total non-current liabilities	13.7	14.7			
Current liabilities					
Trade and other payables	63.4	70.2			
Amounts due to related parties	2.6	3.6			
Bank loans	0.2	0.0			
Total current liabilities	66.2	73.8			
Total liabilities	79.9	88.5			
Equity					
Share capital	18.1	18.1			
Equity	160.6	187.9			
Total equity	178.7	206.0			
Non Controlling interest	2.0	3.1			
Total equity and liabilities	260.6	297.6			

#### Comments

- Increase is primarily from acquisitions beside, replacement medical equipment, IT and clinic roll-out
- Trade receivable days were 70 and 69 as of 31-Dec-2013 and 30-Jun-2014 respectively
- All bank debts were paid off in 2013. The cash position of \$86.3m is after dividends of \$17.7m paid out for 2013 and acquisitions related payment of \$30.5m
- Trade payables days were 58 and 63 as of 31-Dec-2013 and 30-Jun-2014 respectively
  - Trade payables days have increased mainly because of acquisitions and higher inventory stockings at Q2.
- Dividend of \$17.7m was paid in H1 2014 to the shareholders for 2013.